(Practice point) Once an SGLT2i is initiated, it is reasonable to continue an SGLT2i even if the eGFR falls below 30 ml/min per 1.73 m2, unless it is not tolerated or kidney replacement therapy is initiated.(Practice point) SGLT2i have not been adequately studied in kidney transplant recipients, who may benefit from SGLT2i treatment, but are immunosuppressed and potentially at increased risk for infections
In longer terms, oral or inhaled GLP-1 analogues may become a reality
If GLP-1 receptor agonists are accessible only to selected patients with stronger financial resources or better insurance coverage, their use may widen rather than reduce disparities in musculoskeletal care
However, in some lesions one observes small nests of pigmented epithelioid cells entrapped in the collagen
They are not suitable during pregnancy, breastfeeding, or while trying to conceive